The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal.
S
S
Robinson
J
J
Valabhji
M
M
Schachter
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000077154:Rosiglitazone; D013673:Technology Assessment, Biomedical; D013844:Thiazoles / Q000008:administration & dosage*; D045162:Thiazolidinediones; D006113:United Kingdom
D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone